Similar Search Results

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2006

the elasticity of innovation with respect to the expected price of drugs should be at least as great as the elasticity of … innovation with respect to expected market size (disease incidence). I examine the cross-sectional relationship between … pharmaceutical innovation and market size among a set of diseases (different types of cancer) exhibiting substantial exogenous …

Persistent link: https://www.econbiz.de/10005089083

The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2013

I examine the relationship across diseases between the long-run growth in the number of publications about a disease and the change in the age-adjusted mortality rate from the disease. The diseases analyzed are almost all the different forms of cancer, i.e. cancer at different sites in the body...

Persistent link: https://www.econbiz.de/10010969223

The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2012

-year gained) of pharmaceutical innovation was about $12,900. …

Persistent link: https://www.econbiz.de/10010969419

Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2012

I examine the impact of pharmaceutical innovation, as measured by the vintage (world launch year) of prescription drugs …

Persistent link: https://www.econbiz.de/10011265738

Pharmaceutical innovation and the longevity of Australians: a first look

Lichtenberg, Frank; Duflos, Gautier - National Bureau of Economic Research (NBER) - 2008

We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to …

Persistent link: https://www.econbiz.de/10005248962

The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2006

We estimate the medical cost per life-year gained from increased utilization of HIV drugs by estimating the impact of increased drug utilization on the life expectancy and drug and hospital expenditure of HIV/AIDS patients, using aggregate (U.S. national-level) data for the period 1982-2001. We...

Persistent link: https://www.econbiz.de/10005085320

The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2011

We investigate the effect of therapeutic procedure innovation in general on the longevity of all hospital patients, i … patient-level data indicate that therapeutic procedure innovation increased the life expectancy of WA hospital patients by …-level data also indicate that therapeutic procedure innovation increased the life expectancy of WA hospital patients, but the …

Persistent link: https://www.econbiz.de/10009294556

The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2012

I examine the effect of pharmaceutical innovation on the functional status of nursing home residents using cross … dependencies would have been 58%, instead of 50%. During the period 1990-2004, pharmaceutical innovation reduced the functional …

Persistent link: https://www.econbiz.de/10009397140

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1996

This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians in outpatient visits on rates of hospitalization, surgical procedure, mortality, and related variables. It examines the statistical relationship across...

Persistent link: https://www.econbiz.de/10005710396

Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2008

This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We...

Persistent link: https://www.econbiz.de/10005089261